Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Bepotastine Besilate Formulations in Healthy Volunteers
NCT03932435Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bepotastine in allergic rhinitis (AR), urticaria and pruritus (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and Peak Plasma Concentration. Started Apr 2019; status: completed.
02
Drugs
bepotastine
03
Conditions
allergic rhinitis (AR)urticariapruritus
Beyond the preview
Go deeper on NCT03932435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932435.